Cannabis Withdrawal and Sleep Disruption
Insomnia is the most reliable symptom when regular cannabis users quit, and it's the one most likely to push people back to using.
Sleep disruption after quitting cannabis is real, well-documented, and one of the main reasons people relapse. If you've used daily for months or years, expect 1-3 weeks of bad sleep — vivid dreams, trouble falling asleep, frequent waking. This isn't 'in your head' and it isn't a sign you 'need' weed to sleep. It's a predictable rebound effect on REM and slow-wave sleep. The good news: it ends. The bad news: almost nothing works dramatically well to shortcut it, despite what supplement marketing claims.
Plain-language summary
When someone who uses cannabis regularly — especially daily — stops, the body goes through a withdrawal process. Cannabis Withdrawal Syndrome (CWS) is recognized in both the DSM-5 and ICD-11 [1][2]. Sleep disruption is one of its most consistent features, alongside irritability, anxiety, decreased appetite, and restlessness Strong evidence.
The specific sleep problems include: trouble falling asleep, frequent waking, reduced total sleep time, and unusually vivid or disturbing dreams [3][4]. The dream intensity is thought to reflect a rebound in REM sleep, which chronic THC use suppresses Strong evidence.
Symptoms typically start within 1-3 days of stopping, peak in the first week, and resolve within 2-3 weeks, though sleep problems specifically can linger longer than mood or appetite symptoms — sometimes 4-6 weeks in heavy users [3][5].
This article is not medical advice. If you're trying to stop cannabis use and sleep problems are severe or you're considering other substances to cope, talk to a clinician.
What probably works
Time and expectation-setting. The single most evidence-based 'intervention' is knowing the symptoms are temporary and predictable. Studies show people who understand CWS as a finite process relapse less than those who interpret insomnia as a permanent problem [5] Strong evidence.
Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I is first-line treatment for chronic insomnia generally and is recommended by the American College of Physicians [6] Strong evidence. It hasn't been tested heavily in CWS specifically, but its mechanisms — stimulus control, sleep restriction, addressing catastrophic thoughts about sleep — directly target the patterns that drive relapse [evidence:weak when limited to CWS].
Sleep hygiene basics. Consistent wake time, cool dark room, no screens in the hour before bed, no caffeine after early afternoon. These are modest in effect but cheap and have no downside [evidence:weak as standalone, but uncontroversial].
Exercise during the day. Moderate aerobic exercise improves sleep onset and slow-wave sleep in general populations [7] Strong evidence and helps with mood symptoms of withdrawal Weak / limited.
What might work
Gabapentin. One small randomized trial (Mason et al., 2012) found gabapentin reduced cannabis withdrawal symptoms including sleep problems [8] [evidence:weak — single trial, small sample, not replicated at scale].
Nabiximols / dronabinol (pharmaceutical cannabinoids). Several trials show that giving cannabis-dependent patients oral THC or THC/CBD spray during a quit attempt reduces withdrawal severity including sleep symptoms [9][10] [evidence:weak-to-moderate]. This is essentially a tapered withdrawal. It's used clinically in some countries but is not FDA-approved for this indication in the US.
Mirtazapine. A small trial suggested benefit for sleep during cannabis withdrawal [11] Weak / limited. Mirtazapine causes sedation and weight gain, which addresses two withdrawal symptoms at once, but it's a prescription antidepressant with its own profile.
Melatonin. Plausible mechanism for sleep onset; no good trials in CWS specifically. General insomnia data is mixed Weak / limited. Low cost, low risk, reasonable to try.
CBD. Popular suggestion online. The actual evidence for CBD improving sleep is thin and inconsistent at doses people typically use [12] Weak / limited. Some high-dose studies show modest effects; OTC products are usually far below those doses and inconsistently labeled.
What doesn't work or has weak evidence
'Just push through' without any support. People relapse. The 6-month abstinence rate for unsupported quit attempts in daily users is low [5] Strong evidence.
Alcohol as a sleep aid. Disrupts sleep architecture, increases waking in the second half of the night, and risks substituting one substance use disorder for another [evidence:strong against].
Diphenhydramine (Benadryl) and doxylamine. Over-the-counter sedating antihistamines cause grogginess, tolerance develops quickly, and they're associated with worse sleep quality despite faster onset [evidence:weak; generally not recommended for sustained use].
Benzodiazepines and Z-drugs. Effective short-term for sleep but trade one dependence for another with a worse withdrawal profile. Not appropriate as a CWS treatment [evidence:strong against routine use].
Kratom, kava, 'sleep gummies' with proprietary blends. Marketing-driven. No controlled evidence for CWS. Kratom in particular has its own dependence and withdrawal syndrome [13] [evidence:against, based on safety signals].
Going back to cannabis 'just to sleep.' This works the same night. It also restarts the clock on dependence and guarantees the same withdrawal next time you stop [evidence:strong on mechanism].
What we don't know
- Whether CBD specifically helps CWS sleep symptoms at any practical dose [evidence:none of high quality].
- Whether the severity of sleep disruption predicts long-term relapse risk individually (population data exists; individual prediction does not) Weak / limited.
- Why some daily users have minimal withdrawal and others have severe symptoms. Genetics, baseline sleep, dose, route, and concurrent mental health all play roles, but no validated predictive model exists No data.
- Whether tapering is meaningfully better than abrupt cessation for sleep outcomes specifically. Some trials suggest yes, others find no difference Disputed.
- Long-term sleep architecture in former heavy users — does REM and slow-wave sleep fully normalize, and on what timeline? Limited longitudinal data Weak / limited.
Comparison with standard insomnia treatment
Standard chronic insomnia care, per the American Academy of Sleep Medicine and American College of Physicians, is CBT-I first, then short-term pharmacotherapy if needed [6][14]. For CWS-related insomnia, the same hierarchy mostly applies, with two caveats:
- It's time-limited. Unlike chronic primary insomnia, CWS insomnia resolves on its own. The job of treatment is to bridge 2-4 weeks, not manage indefinitely. This argues against starting long-term medications.
- The underlying issue is a substance use disorder. Pure sleep treatment without addressing cannabis use will keep failing if the person resumes daily use. Integrated treatment — sleep support plus motivational interviewing or contingency management for cannabis use disorder — outperforms either alone [15] [evidence:moderate].
Risks and when to see a clinician
CWS itself is not medically dangerous — unlike alcohol or benzodiazepine withdrawal, it does not cause seizures or delirium Strong evidence. The main risks are:
- Relapse driven by insomnia. Most common adverse outcome.
- Substitution with worse substances (alcohol, benzodiazepines, opioids) to sleep.
- Mood symptoms. Depression and suicidal ideation can emerge or worsen during withdrawal in vulnerable people [3]. This is the most important reason to involve a clinician if symptoms are severe.
- Misdiagnosis. Pre-existing insomnia, sleep apnea, or an anxiety disorder may have been masked by cannabis use and become visible after quitting. These need their own workup.
See a clinician if: sleep problems persist beyond 6 weeks, you're having thoughts of self-harm, you're using alcohol or other sedatives to cope, or you've tried to quit multiple times unsuccessfully.
This article is informational and is not medical advice. It does not replace evaluation by a qualified clinician.
Sources
- Book American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Cannabis Withdrawal, pp. 517-519.
- Government World Health Organization. ICD-11 for Mortality and Morbidity Statistics, 6C41.4 Cannabis withdrawal. ↗
- Peer-reviewed Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161(11), 1967-1977.
- Peer-reviewed Bolla, K. I., Lesage, S. R., Gamaldo, C. E., et al. (2008). Sleep disturbance in heavy marijuana users. Sleep, 31(6), 901-908.
- Peer-reviewed Allsop, D. J., Copeland, J., Norberg, M. M., et al. (2012). Quantifying the clinical significance of cannabis withdrawal. PLoS ONE, 7(9), e44864.
- Peer-reviewed Qaseem, A., Kansagara, D., Forciea, M. A., et al. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.
- Peer-reviewed Kredlow, M. A., Capozzoli, M. C., Hearon, B. A., Calkins, A. W., & Otto, M. W. (2015). The effects of physical activity on sleep: a meta-analytic review. Journal of Behavioral Medicine, 38(3), 427-449.
- Peer-reviewed Mason, B. J., Crean, R., Goodell, V., et al. (2012). A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37(7), 1689-1698.
- Peer-reviewed Allsop, D. J., Copeland, J., Lintzeris, N., et al. (2014). Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry, 71(3), 281-291.
- Peer-reviewed Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011). Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 116(1-3), 142-150.
- Peer-reviewed Haney, M., Hart, C. L., Vosburg, S. K., et al. (2010). Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology, 211(2), 233-244.
- Peer-reviewed Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019). Cannabidiol in anxiety and sleep: a large case series. The Permanente Journal, 23, 18-041.
- Government U.S. Food and Drug Administration. FDA and Kratom — safety communications and warnings. ↗
- Peer-reviewed Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307-349.
- Peer-reviewed Budney, A. J., Stanger, C., Knapp, A. A., & Walker, D. D. (2021). Status update on the treatment of cannabis use disorder. Substance Abuse, 42(3), 248-256.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...